Cancer Letters
Volume 241, Issue 1 , Pages 23-30 , 8 September 2006

Delivery of hypericin for photodynamic applications

  • Constance Lay Lay Saw

      Affiliations

    • Department of Pharmacy, National University of Singapore, 18 Science Drive 4, Singapore, Singapore 117543
    • ,
  • Malini Olivo

      Affiliations

    • Division of Medical Sciences, National Cancer Centre Singapore, Singapore, Singapore 169610
    • ,
  • Khee Chee Soo

      Affiliations

    • Division of Medical Sciences, National Cancer Centre Singapore, Singapore, Singapore 169610
    • ,
  • Paul Wan Sia Heng

      Affiliations

    • Department of Pharmacy, National University of Singapore, 18 Science Drive 4, Singapore, Singapore 117543
    • Corresponding Author InformationCorresponding author. Tel.: +65 6874 2930; fax: +65 6775 2265.

Received 3 August 2005 ,Revised 17 October 2005 ,Accepted 18 October 2005.

References 

  1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics. Cancer J. Clin. 2005;55:10–30
  2. Borden LS, Clark PE, Hall MC. Bladder cancer. Curr. Opin. Oncol. 2003;15:227–233
  3. A. Seow, W.P. Koh, K.S. Chia, L.M. Shi, H.P. Lee, K. Shanmugaratnam, Trends in cancer incidence in Singapore 1968–2002, Singapore Cancer Registry Report No. 6, 2004, p. 132.
  4. Jichlinski P. New diagnostic strategies in the detection and staging of bladder cancer. Curr. Opin. Urol. 2003;13:351–355
  5. Jichlinski P, Leisinger HJ. Fluorescence cystoscopy in the management of bladder cancer: a help for the urologist!. Urol. Int. 2005;74:97–101
  6. D'Hallewin MA, De Witte PA, Waelkens E, Merlevede W, Baert L. Fluorescence detection of flat bladder carcinoma in situ after intravesical instillation of hypericin. J. Urol. 2000;164:349–351
  7. Sim HG, Lau WKO, Olivo M, Tan PH, Cheng CWS. Is photodynamic diagnosis using hypericin better than white-light cystoscopy for detecting superficial bladder carcinoma?. BJU Int. 2005;95:1215–1218
  8. Kriegmair M, Ehsan A, Baumgartner R, Lumper W, Knuechel R, Hofstadter F, et al. Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology. 1994;44:836–841
  9. Jichlinski P, Forrer M, Mizeret J, Glanzmann T, Braichotte D, Wagnieres G, et al. Clinical evaluation of a method for detecting superficial transitional cell carcinoma of the bladder by light-induced fluorescence of protoporphyrin IX following topical application of 5-aminolevulinic acid: preliminary results. Lasers Surg. Med. 1997;20:402–408
  10. Koenig F, McGovern FJ, Larne R, Enquist H, Schomacker KT, Deutsch TF. Diagnosis of bladder carcinoma using protoporphyrin IX fluorescence induced by 5-aminolaevulinic acid. BJU Int. 1999;83:129–135
  11. Lange N, Jichlinski P, Zellweger M, Forrer M, Marti A, Guillou L, et al. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br. J. Cancer. 1999;80:185–193
  12. Jichlinski P, Guillou L, Karlsen SJ, Malmstrom PU, Jocham D, Brennhovd B, et al. Hexyl aminolevulinate fluorescence cystoscopy: a new diagnostic tool for the photodiagnosis of superficial bladder cancer—a multicenter study. J. Urol. 2003;170:226–229
  13. D'Hallewin MA, Kamuhabwa AR, Roskams T, De Witte PA, Baert L. Hypericin-based fluorescence diagnosis of bladder carcinoma. BJU Int. 2002;89:760–763
  14. Agostinis P, Vantieghem A, Merlevede W, De Witte PA. Hypericin in cancer treatment: more light on the way. Int. J. Biochem. Cell Biol. 2002;34:221–241
  15. Kriegmair M, Baumgartner R, Knuchel R, Stepp H, Hofstadter F, Hofstetter A. Detection of early bladder cancer by 5-aminolevulinic acid induced porphyrin fluorescence. J Urol. 1996;155:105–109(discussion 109–110)
  16. D'Hallewin MA, Bezdetnaya L, Guillemin F. Fluorescence detection of bladder cancer: a review. Eur. Urol. 2002;42:417–425
  17. Brunner H, Hausmann F, Krieg RC, Endlicher E, Scholmerich J, Knuechel R, et al. The effects of 5-aminolevulinic acid esters on protoporphyrin IX production in human adenocarcinoma cell lines. Photochem. Photobiol. 2001;74:721–725
  18. Uehlinger P, Zellweger M, Wagnieres G, Juillerat-Jeanneret L, van den Bergh H, Lange N. 5-Aminolevulinic acid and its derivatives: physical chemical properties and protoporphyrin IX formation in cultured cells. J. Photochem. Photobiol. B. 2000;54:72–80
  19. Novo M, Huttmann G, Diddens H. Chemical instability of 5-aminolevulinic acid used in the fluorescence diagnosis of bladder tumours. J. Photochem. Photobiol. B. 1996;34:143–148
  20. Marti A, Lange N, van den Bergh H, Sedmera D, Jichlinski P, Kucera P. Optimisation of the formation and distribution of protoporphyrin IX in the urothelium: an in vitro approach. J. Urol. 1999;162:546–552
  21. Cosserat-Gerardin I, Bezdetnaya L, Notter D, Vigneron C, Guillemin F. Biosynthesis and photodynamic efficacy of protoporphyrin IX (PpIX) generated by 5-aminolevulinic acid (ALA) or its hexylester (hALA) in rat bladder carcinoma cells. J. Photochem. Photobiol. B. 2000;59:72–79
  22. Zaak D, Karl A, Knuchel R, Stepp H, Hartmann A, Reich O, et al. Diagnosis of urothelial carcinoma of the bladder using fluorescence endoscopy. BJU Int. 2005;96:217–222
  23. Kamuhabwa A, Agostinis P, Ahmed B, Landuyt W, van Cleynenbreugel B, van Poppel H, et al. Hypericin as a potential phototherapeutic agent in superficial transitional cell carcinoma of the bladder. Photochem. Photobiol. Sci. 2004;3:772–780
  24. Lavie G, Mazur Y, Lavie D, Meruelo D. The chemical and biological properties of hypericin—a compound with a broad-spectrum of biological-activities. Med. Res. Rev. 1995;15:111–119
  25. Kubin A, Wierrani F, Burner U, Alth G, Grunberger W. Hypericin–the facts about a controversial agent. Curr. Pharm. Des. 2005;11:233–253
  26. Koren H, Schenk GM, Jindra RH, Alth G, Ebermann R, Kubin A, et al. Hypericin in phototherapy. J. Photochem. Photobiol. B. 1996;36:113–119
  27. Miskovsky P. Hypericin–a new antiviral and antitumor photosensitizer: mechanism of action and interaction with biological macromolecules. Curr. Drug Targets. 2002;3:55–84
  28. Schinazi RF, Chu CK, Babu JR, Oswald BJ, Saalmann V, Cannon DL, et al. Anthraquinones as a new class of antiviral agents against human-immunodeficiency-virus. Antiviral Res. 1990;13:265–272
  29. Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat. Rev. Cancer. 2003;3:380–387
  30. Huygens A, Kamuhabwa AR, De Witte PAM. Stability of different formulations and ion pairs of hypericin. Eur. J. Pharm. Biopharm. 2005;59:461–468
  31. Huygens A, Kamuhabwa AR, van Cleynenbreugel B, van Poppel H, Roskams T, De Witte PA. In vivo accumulation of different hypericin ion pairs in the urothelium of the rat bladder. Brit. J. Urol. Int. 2005;95:436–441
  32. C.L. Saw, P.W. Heng, W.W. Chin, K.C. Soo, M. Olivo, Enhanced photodynamic activity of hypericin by penetration enhancer N-methyl pyrrolidone formulations in the chick chorioallantoic membrane model, Cancer Lett. (available online 28 July 2005).
  33. Saw CL, Olivo M, Chin WW, Soo KC, Heng PW. Transport of hypericin across chick chorioallantoic membrane and photodynamic therapy vasculature assessment. Biol. Pharm. Bull. 2005;28:1054–1060
  34. Uzdensky AB, Bragin DE, Kolosov MS, Kubin A, Loew HG, Moan J. Photodynamic effect of hypericin and a water-soluble derivative on isolated crayfish neuron and surrounding glial cells. J. Photochem. Photobiol. B. 2003;72:27–33
  35. Kamuhabwa AR, Geboes KR, De Witte PA. Investigation of the absorption of hypericin into the skin of hairless mice. J. Pharm. Pharmacol. 2000;52:487–494
  36. Kamuhabwa AR, Roelandts R, De Witte PA. Skin photosensitization with topical hypericin in hairless mice. J. Photochem. Photobiol. B. 1999;53:110–114
  37. Sattler S, Schaefer U, Schneider W, Hoelzl J, Lehr CM. Binding, uptake, and transport of hypericin by caco-2 cell monolayers. J. Pharm. Sci. 1997;86:1120–1126
  38. Ebermann R, Alth G, Kreitner M, Kubin A. Natural products derived from plants as potential drugs for the photodynamic destruction of tumor cells. J. Photochem. Photobiol. B. 1996;36:95–97
  39. Falk H. From the photosensitizer hypericin to the photoreceptor stentorin—the chemistry of phenanthroperylene quinones. Angew. Chem. Int. Ed. Engl. 1999;38:3116–3136
  40. Falk H, Meyer J, Oberreiter M. A convenient semisynthetic route to hypericin. Monatsh. Chem. 1993;124:339–341
  41. Derycke ASL, De Witte PAM. Liposomes for photodynamic therapy. Adv. Drug Deliv. Rev. 2004;56:17–30
  42. Vargas A, Pegaz B, Debefve E, Konan-Kouakou Y, Lange N, Ballini JP, et al. Improved photodynamic activity of porphyrin loaded into nanoparticles: an in vivo evaluation using chick embryos. Int. J. Pharm. 2004;286:131–145
  43. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer. 2001;37:1590–1598
  44. Konan YN, Gurny R, Allemann E. State of the art in the delivery of photosensitizers for photodynamic therapy. J. Photochem. Photobiol. B. 2002;66:89–106
  45. Miskovsky P, Sureau F, Chinsky L, Turpin PY. Subcellular distribution of hypericin in human cancer cells. Photochem. Photobiol. 1995;62:546–549
  46. Kamuhabwa AR, Augustijns P, De Witte PA. In vitro transport and uptake of protohypericin and hypericin in the Caco-2 model. Int. J. Pharm. 1999;188:81–86
  47. Chen B, De Witte PA. Photodynamic therapy efficacy and tissue distribution of hypericin in a mouse P388 lymphoma tumor model. Cancer Lett. 2000;150:111–117
  48. Andreoni A, Colasanti A, Colasanti P, Mastrocinque M, Riccio P, Roberti G. Laser photosensitization of cells by hypericin. Photochem. Photobiol. 1994;59:529–533
  49. Chung PS, Saxton RE, Paiva MB, Rhee CK, Soudant J, Mathey A, et al. Hypericin uptake in rabbits and nude mice transplanted with human squamous cell carcinomas: study of a new sensitizer for laser phototherapy. Laryngoscope. 1994;104:1471–1476
  50. Hidalgo IJ. Assessing the absorption of new pharmaceuticals. Curr. Top. Med. Chem. 2001;1:385–401
  51. Kamuhabwa AR, Agostinis P, D'Hallewin MA, Kasran A, De Witte PA. Photodynamic activity of hypericin in human urinary bladder carcinoma cells. Anticancer Res. 2000;20:2579–2584
  52. Das K, Smirnov AV, Wen J, Miskovsky P, Petrich JW. Photophysics of hypericin and hypocrellin A in complex with subcellular components: interactions with human serum albumin. Photochem. Photobiol. 1999;69:633–645
  53. Theodossiou T, Spiro MD, Jacobson J, Hothersall JS, Macrobert AJ. Evidence for intracellular aggregation of hypericin and the impact on its photocytotoxicity in PAM 212 murine keratinocytes. Photochem. Photobiol. 2004;80:438–443
  54. Kelbauskas L, Dietel W. Internalization of aggregated photosensitizers by tumor cells: subcellular time-resolved fluorescence spectroscopy on derivatives of pyropheophorbide-a ethers and chlorin e6 under femtosecond one- and two-photon excitations. Photochem. Photobiol. 2002;76:686–694
  55. Uzdensky AB, Ma LW, Iani V, Hjortland GO, Steen HB, Moan J. Intracellular localisation of hypericin in human glioblastoma and carcinoma cell lines. Lasers Surg. Med. 2001;16:276–283
  56. Thomas C, Pardini RS. Oxygen dependence of hypericin-induced phototoxicity to EMT6 mouse mammary carcinoma cells. Photochem. Photobiol. 1992;55:831–837
  57. Weber ND, Murray BK, North JA, Wood SG. The antiviral agent hypericin has in-vitro activity against Hsv-1 through nonspecific association with viral and cellular membranes. Antivir. Chem. Chemother. 1994;5:83–90
  58. Huygens A, Kamuhabwa AR, Roskams T, van Cleynenbreugel B, van Poppel H, De Witte PA. Permeation of hypericin in spheroids composed of different grade transitional cell carcinoma cell lines and normal human urothelial cells. J. Urol. 2005;174:69–72
  59. Du HY, Bay BH, Olivo M. Biodistribution and photodynamic therapy with hypericin in a human NPC murine tumor model. Int. J. Oncol. 2003;22:1019–1024
  60. Chen B, Roskams T, De Witte PA. Antivascular tumor eradication by hypericin-mediated photodynamic therapy. Photochem. Photobiol. 2002;76:509–513
  61. Chen B, Roskams T, Xu Y, Agostinis P, De Witte PA. Photodynamic therapy with hypericin induces vascular damage and apoptosis in the RIF-1 mouse tumor model. Int. J. Cancer. 2002;98:284–290
  62. Chen B, Xu Y, Roskams T, Delaey E, Agostinis P, Vandenheede JR, et al. Efficacy of antitumoral photodynamic therapy with hypericin: relationship between biodistribution and photodynamic effects in the RIF-1 mouse tumor model. Int. J. Cancer. 2001;93:275–282
  63. Chen B, Zupko I, De Witte PA. Photodynamic therapy with hypericin in a mouse P388 tumor model: vascular effects determine the efficacy. Int. J. Oncol. 2001;18:737–742
  64. Kamuhabwa AAR, Cosserat-Gerardin I, Didelon J, Notter D, Guillemin F, Roskams T, et al. Biodistribution of hypericin in orthotopic transitional cell carcinoma bladder tumors: implication for whole bladder wall photodynamic therapy. Int. J. Cancer. 2002;97:253–260
  65. Sartor O. Eligard: leuprolide acetate in a novel sustained-release delivery system. Urology. 2003;61:25–31
  66. Moreau JP, Vachon PJ, Huneau MC. Elevated glycemia and local inflammation after injecting N-methyl-2-pyrrolidone (NMP) into the marginal ear vein of rabbits. Contemp. Top. Lab. Anim. Sci. 2001;40:38–40
  67. Akesson B, Paulsson K. Experimental exposure of male volunteers to N-methyl-2-pyrrolidone (NMP): acute effects and pharmacokinetics of NMP in plasma and urine. Occup. Environ. Med. 1997;54:236–240
  68. Leira HL, Tiltnes A, Svendsen K, Vetlesen L. Irritant cutaneous reactions to N-methyl-2-pyrrolidone (NMP). Contact Dermatitis. 1992;27:148–150

PII: S0304-3835(05)00940-7

doi: 10.1016/j.canlet.2005.10.020

Cancer Letters
Volume 241, Issue 1 , Pages 23-30 , 8 September 2006

Article Tools